Compressed air initiates the solution into the dermis
Kinetic impact captures an area in the range of 8 mm
Microdrop system activates immune response and cell communication
Injection
Pneumatic volumetric injection by SHEMAX TPI
Dozens of procedures with just one device
Kinetic impact captures an area in the range of 8 mm
Botulinum, bioreparant, collagen, etc.
How it works?
AIR COMPRESSOR
AIR RESERVOIR
AIR PRESSURE CONTROL
Contains compressed air
Compressed air initiates the solution into the dermis
Kinetic impact captures an area in the range of 8 mm
Microdrop system activates immune response and cell communication
Provides pressure control and air supply to the nozzle according to the operator's settings
KINETIC ENERGY
PNEUMATIC ENERGY
PNEUMATIC ENERGY
How it works?
Compressed air initiates the solution into the dermis
Kinetic impact captures an area in the range of 8 mm
Microdrop system activates immune response and cell communication
KINETIC ENERGY
PNEUMATIC ENERGY
PNEUMATIC ENERGY
Swipe left to see
How it works?
AIR COMPRESSOR
AIR RESERVOIR
AIR PRESSURE CONTROL
Contains compressed air
Compressed air initiates the solution into the dermis
Kinetic impact captures an area in the range of 8 mm
Microdrop system activates immune response and cell communication
Provides pressure control and air supply to the nozzle according to the operator's settings
KINETIC ENERGY
PNEUMATIC ENERGY
PNEUMATIC ENERGY
AIR COMPRESSOR
AIR RESERVOIR
AIR PRESSURE CONTROL
Contains compressed air
Provides pressure control and air supply to the nozzle according to the operator's settings
Nozzles: for face (reduced nozzle) for body (enlarged nozzle)
Face and body kits (separately) are supplied with the SHEMAX TPI device, along with individual packages, nozzle + syringe
CONSUMABLES FOR THE DEVICE
Syringe for drawing and administering solution into the nozzle
Swipe left to see
CYLINDER
To supply compressed air from the air reservoir
CONSUMABLES FOR THE DEVICE
Face and body kits (separately) are supplied with the SHEMAX TPI device, along with individual packages, nozzle + syringe
Nozzles: for face (reduced nozzle) for body (enlarged nozzle)
Syringe for drawing and administering solution into the nozzle
NOZZLE FOR INTRODUCING THE SOLUTION
SYRINGE FOR ADMINISTERING SOLUTION
CYLINDER
To supply compressed air from the air reservoir
NOZZLE FOR INTRODUCING THE SOLUTION
SYRINGE FOR ADMINISTERING SOLUTION
High Procedure Speed
SHEMAX TPI is not limited to the action of a specific solution, it also affects the target layer of the skin in a wide range and creates pneumatic injector exposure zones, which promotes the formation of nerve fibers and skin regeneration
MANUAL SETTINGS
Control of injected drug and pressure depending on tasks and zone
SHEMAX TPI is not limited to the action of a specific solution, it also affects the target layer of the skin in a wide range and creates pneumatic injector exposure zones, which promotes the formation of nerve fibers and skin regeneration
Adjustable Solution Volume
Setting the pneumatic flow and solution volume for a specific result
Stages of treatments
Remodeling and rejuvenation of skin tissue
Immediate lifting effect after treatment with gualuronic acid or any other injectable solution
Pressure spraying of the solution into the skin layers under high pressure up to 6 mm on the face, and up to 8 mm on the body
Comparative study of percutaneous pneumatic injection therapy with isotonic and hypertonic glucose solution with different treatment options for different facial areas (split-face study)
Pneumatic injection-induced percutaneous penetration of hypertonic glucose solution: analysis of macro- and microscopic characteristics in human and rat tissues
Percutaneous pneumatic injections of hypertonic glucose solution with pressure and dose control in the correction of atrophic skin changes
Needle-free, pressure- and dose-controlled percutaneous pneumatic injections of botulinum toxin type A in the treatment of primary axillary and palmar-subcutaneous hyperhidrosis
Comparative study of percutaneous pneumatic injection therapy with isotonic and hypertonic glucose solution with different treatment options for different facial areas (split-face study)
Percutaneous pneumatic injections of hypertonic glucose solution with pressure and dose control in the correction of atrophic skin changes
Immediately after PIT, bluish homogeneous entry points into the epidermis were detected in all cadaver tissue samples (see Fig. 1A).
Skin-colored papules about 1 cm in size were observed around the entry points. After dissection of the epidermis, dermis, and adipose tissue, rounded or oval areas of bluish 20% hypertonic glucose solution infiltration were detected in the subcutaneous fatty tissue layer of all halves of the face
Figure 1. Pneumatic Injection Treatment (PIT) of human corpse tissues. (A) Pin blue entrance holes in the epidermis formed after PIT. Areas of PIT with 20% hypertonic glucose solution in (B) subcutaneous adipose (SC) tissue and superficial temporal fascia (STF), (C) superficial layer of deep temporal fascia (sDTF) and deep layer of deep temporal fascia (dDTF). SK is skin.
Medical Lasers, Hyun-Jo Kim et al.. Medical Lasers; Engineering, Basic Research, and Clinical Application (Medical lasers; engineering, basic research, and clinical applications)
Immediately after PIT, bluish homogeneous entry points into the epidermis were detected in all cadaver tissue samples (see Fig. 1A).
Skin-colored papules about 1 cm in size were observed around the entry points. After dissection of the epidermis, dermis, and adipose tissue, rounded or oval areas of bluish 20% hypertonic glucose solution infiltration were detected in the subcutaneous fatty tissue layer of all halves of the face
Medical Lasers, Hyun-Jo Kim et al.. Medical Lasers; Engineering, Basic Research, and Clinical Application (Medical lasers; engineering, basic research, and clinical applications)
IN VIVO testing of human tissues immediately after PIO (Percutaneous Injection of Solution) using 2D ultrasound.
Areas: Forehead along the hairline; skin in the abdominal region.
Settings: SURFACE. PRESSURE: 2.05 bar and injection volume of 0.12 ml per injection. OBSERVED: Well-defined areas of glucose solution infiltration in the dermis and at the transition area between the dermis and subcutaneous adipose tissue (average height: 3.5 ± 0.5 mm; average width: 9.2 ± 0.4 mm) see Fig. 3A.
Figure 3. Ultrasound examination. Two-dimensional ultrasound images showing PIT zones (circled in white circles) immediately after PIT of human non-hair-covered skin along the hair growth line in the forehead region using a 20% hypertonic glucose solution under in vivo conditions. PIT settings were as follows: injection volume 0.12 ml/injection and pressures (A) 2.05 bar, (B) 2.55 bar, (C) 3.15 bar, and (D) 3.63 bar. A hockey stick-shaped linear high-frequency sensor with a frequency of 8-17 MHz was used for imaging. Asterisks indicate acoustic shading. E, epidermis; D, dermis; S, subcutaneous fat; FM, fascia and muscles; PO, periosteum.
Medical Lasers, Hyun-Jo Kim et al.. Medical Lasers; Engineering, Basic Research, and Clinical Application (Medical lasers; engineering, basic research, and clinical applications)
IN VIVO testing of human tissues immediately after PIO (Percutaneous Injection of Solution) using 2D ultrasound. Areas: Forehead along the hairline; skin in the abdominal region.
Settings: SURFACE. PRESSURE: 2.05 bar and injection volume of 0.12 ml per injection. OBSERVED: Well-defined areas of glucose solution infiltration in the dermis and at the transition area between the dermis and subcutaneous adipose tissue (average height: 3.5 ± 0.5 mm; average width: 9.2 ± 0.4 mm) see Fig. 3A.
Medical Lasers, Hyun-Jo Kim et al.. Medical Lasers; Engineering, Basic Research, and Clinical Application (Medical lasers; engineering, basic research, and clinical applications)
Figure 3. Ultrasound examination. Two-dimensional ultrasound images showing PIT zones (circled in white circles) immediately after PIT of human non-hair-covered skin along the hair growth line in the forehead region using a 20% hypertonic glucose solution under in vivo conditions. PIT settings were as follows: injection volume 0.12 ml/ injection and pressures (A) 2.05 bar, (B) 2.55 bar, (C) 3.15 bar, and (D) 3.63 bar. A hockey stick -shaped linear high-frequency sensor with a frequency of 8-17 MHz was used for imaging. Asterisks indicate acoustic shading. E, epidermis; D, dermis; S, subcutaneous fat; FM, fascia and muscles; PO, periosteum.